Literature DB >> 22841425

Evaluation of whether intracameral dexamethasone predisposes to glaucoma after pediatric cataract surgery.

Asimina Mataftsi1, Ahmad Dabbagh, Will Moore, Ken K Nischal.   

Abstract

PURPOSE: To evaluate the effect of intracameral dexamethasone during pediatric cataract surgery on the incidence of postoperative glaucoma.
SETTING: Clinical and Academic Department of Ophthalmology, Great Ormond Street Hospital, London, United Kingdom.
DESIGN: Retrospective case series.
METHODS: This case-note review comprised all infants who had cataract surgery with intraocular lenses between January 1, 2007, and December 31, 2008, and were given preservative-free intracameral dexamethasone intraoperatively. The definition of glaucoma was an intraocular pressure (IOP) of 21 mm Hg or greater on more than 2 occasions or moderate or firm digital IOP with 1 of the following: myopic shift, increased cup-to-disc ratio, increased horizontal corneal diameter, or corneal edema.
RESULTS: Eighteen patients (24 eyes) were included. The median age at surgery was 3 months (mean 4 months ± 3 (SD); range 1 to 11 months). The median follow-up was 38 months (mean 34 ± 10 months; range 20 to 48 months). In 4 eyes, transient postoperative antihypertensive medication was used; however, no eye developed glaucoma during the follow-up period. Fifteen eyes had a second procedure to clear the visual axis due to posterior visual axis opacification a mean of 6.4 ± 3.5 months postoperatively (median 4.8 months; range 3.5 to 14.5 months); however, no eye developed anterior membranes.
CONCLUSION: Intracameral preservative-free dexamethasone in infantile cataract surgery did not seem to cause an increased risk for glaucoma and appeared to protect against anterior membrane formation.
Copyright © 2012 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841425     DOI: 10.1016/j.jcrs.2012.05.034

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  3 in total

1.  The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery.

Authors:  Gaokun Zhang; Shuang Liu; Lieying Yang; Yanqing Li
Journal:  Exp Ther Med       Date:  2017-12-15       Impact factor: 2.447

2.  Comparison of intracameral dexamethasone and intracameral triamcinolone acetonide injection at the end of phacoemulsification surgery.

Authors:  Gokhan Ozge; Onder Ayyildiz; Murat Kucukevcilioglu; Tarkan Mumcuoglu
Journal:  Indian J Ophthalmol       Date:  2015-03       Impact factor: 1.848

Review 3.  Pediatric cataract: challenges and future directions.

Authors:  Anagha Medsinge; Ken K Nischal
Journal:  Clin Ophthalmol       Date:  2015-01-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.